Connection
David Camidge to Cost-Benefit Analysis
This is a "connection" page, showing publications David Camidge has written about Cost-Benefit Analysis.
|
|
Connection Strength |
|
|
|
|
|
0.238 |
|
|
|
-
Whittington MD, Atherly AJ, Bocsi GT, Camidge DR. A Primer on Health Economic Evaluations in Thoracic Oncology. J Thorac Oncol. 2016 08; 11(8):1224-1232.
Score: 0.113
-
Atherly AJ, Camidge DR. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br J Cancer. 2012 Mar 13; 106(6):1100-6.
Score: 0.085
-
Smare C, Dave K, Juarez-Garcia A, Abraham P, Penrod JR, Camidge DR, Yuan Y. Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer. J Med Econ. 2021 Jan-Dec; 24(1):1124-1133.
Score: 0.039